Purpose {#S0001}
=======

Prostate brachytherapy is commonly used for the definitive treatment of prostate cancer. Brachytherapy using permanent implantation of low-dose-rate (LDR) seeds alone for clinically localized prostate cancer can be achieved in a single outpatient visit. It allows for a higher dose of radiation to be given to the prostate while minimizing radiation exposure to the surrounding normal structures, and has similar efficacy to radical prostatectomy or external beam radiation therapy \[[@CIT0001]--[@CIT0003]\]. However, brachytherapy requires accurate placement of radioactive seeds and is more operator-dependent than external beam radiation therapy (EBRT), and implant quality can impact long-term outcome \[[@CIT0004], [@CIT0005]\].

Quality assurance mandates a post-implant computed tomography (CT) scan to ensure proper implant positioning, and dosimetric parameters such as the D~90~ and V~100~ of the whole prostate (WP) are used to assess treatment adequacy \[[@CIT0006]\]. The majority of prostate cancers, however, occur in the peripheral zone, and the WP dosimetric parameters do not account for the zonal anatomy of the prostate nor capture the heterogeneity in dose distribution within the prostate \[[@CIT0007], [@CIT0008]\]. Herein, the influence of zone-specific dosimetry on rates of biochemical failure and toxicity is described.

Material and methods {#S0002}
====================

Study design {#S20003}
------------

This was an Institutional Review Board (IRB) approved retrospective review of 416 patients treated between 1996 and 2003 at our institution. All patients were treated according to the American Brachytherapy Society (ABS) guidelines for I-125 permanent prostate implantation (PI) (target dose of 144 Gy to the prostate), and no patient was excluded from therapy based on pre-operative urinary function or prostate volume. None of our patients were included in the RTOG 98-05 study.

Brachytherapy technique {#S20004}
-----------------------

Transrectal ultrasound (TRUS) images of the prostate were obtained at 0.5 cm intervals using the brachytherapy stepper (Amertek Medical Inc, Singer Island, FL, USA). Intra-operative physics planning was done with a 0.5 cm radial margin at the apex and base, ensuring that the urethra did not overlap with the 150% isodose line, and V~100%~ of the rectum was less than 1 cm^3^ (VariSeed 8.0, Varian Medical Systems, Palo Alto, CA) \[[@CIT0009]\]. Rapid strands were placed peripherally and loose seeds were placed centrally; needles were placed beginning with the position furthest from the ultrasound probe to minimize image distortion.

Evaluation of dosimetric quantifiers and clinical variables {#S20005}
-----------------------------------------------------------

The volumes of the whole prostate were already contoured on post-implant CT scans as part of the standard quality assurance process and calculation of D~90~ and V~100~ for clinical purposes. As the contours by treating physicians were used as a reference for contouring the transitional zone (TZ) and peripheral zone (PZ), the WP was not re-contoured for this study. The TZ was contoured as an area of similar shape to the WP but extending to approximately half of the anterio-posterior diameter of the prostate on axial CT slices ([Fig. 1](#F0001){ref-type="fig"}). The PZ was defined to be the remainder of the previously contoured prostate that was not included in the TZ. This method was chosen in order to yield zonal volumes that are consistent with known relative sizes of each zone of the prostate \[[@CIT0010], [@CIT0011]\]. Urethral dose was not quantified as imaging was performed without catheter placement. Post-implant dosimetric analysis was performed according to ABS guidelines, and D~90~, D~100~, V~100~, V~150~, V~200~, V~300~, and V~400~ were calculated for the WP, TZ, and PZ. Pairwise *t*-tests comparing V~100~ (as a percentage of the zone volume) and D~90~ (in Gy) between zones of the prostate were done.

![Transition zone (TZ) (orange) and peripheral zone (PZ) (purple) are contoured on axial slices of the post-implant prostate computed tomography. Whole prostate (WP) (red) and rectum (blue) were already contoured as part of the standard QA process](JCB-7-24538-g001){#F0001}

Clinical and treatment characteristics were examined as well, including the duration of androgen deprivation therapy (ADT), race, clinical stage, initial prostate-specific antigen (PSA), Gleason score, National Comprehensive Cancer Network risk stratification, and post PI PSA measurements ([Table 1](#T0001){ref-type="table"}). Biochemical failure was defined using the Phoenix criteria (increase in 2.0 ng/ml over nadir PSA) \[[@CIT0012]\]. Five-year and 10-year rates for biochemical recurrence-free survival, distant metastasis-free survival, and prostate cancer-specific mortality were computed. Only patients with three or more PSA measurements were included in the analysis of biochemical recurrence-free survival, as two PSA measurements are required for the definition of biochemical recurrence, and a third is needed to rule out PSA bounce.

###### 

Characteristics of the study population

  Characteristic                       Median or *n*   Range or%
  ------------------------------------ --------------- -----------
  Age (years)                          68              45-87
  Initial PSA                          6.1             0.4-33.9
  Race                                                 
   Non-African American                366             88.0
   African American                    50              12.0
  Clinical T stage                                     
   T1-T2a                              406             97.6
   T2b or T2c                          10              2.4
  Initial PSA (ng/ml)                                  
   \< 4                                41              9.9
   4-10                                317             76.2
   10-20                               54              13.0
   \> 20                               4               1.0
  Gleason score                                        
   6                                   329             79.1
   7                                   82              19.7
   8-10                                5               1.2
  NCCN risk category                                   
   Low                                 279             67.1
   Intermediate                        112             26.9
   High                                25              6.0
  ADT                                                  
   None                                331             79.6
   1-6 months                          74              17.8
   \> 6 months                         11              2.6
  Biochemical failure                                  
   No                                  369             88.7
   Yes                                 47              11.3
  Distant metastases                                   
   No                                  398             95.7
   Yes                                 18              4.3
  Follow-up time (years)               8.8             0.2-15.1
  Number of post PI PSA measurements   9               0-41
  PSA frequency (\#PSAs/year)          1.5             0.3-12
  Status                                               
   Alive                               326             78.4
   Dead, of disease                    5               1.2
   Dead, other                         85              20.4

Numbers and percentages are provided for categorical variables; medians and ranges are provided for continuous variables.

ADT -- androgen deprivation therapy, PI -- prostate implant, NED -- no evidence of disease

Toxicity data was collected during clinical follow-up visits, and analyzed retrospectively. Toxicity was scored according to Common Terminology Criteria for Adverse Events (CTCAE) version 4.0 criteria, and descriptive statistics for late genitourinary (GU) and gastrointestinal (GI) toxicity was tabulated \[[@CIT0013]\]. Five-year and 10-year rates for grade 3 or higher late GU and GI toxicity were computed using Kaplan-Meier analysis.

Statistical analysis {#S20006}
--------------------

Statistical analysis was performed using SAS 9.2 and JMP 9.0 software (SAS Institute, Cary, NC, USA). Cox proportional hazards regression was used to assess clinical and dosimetric parameters as predictors for bio-chemical failure and late toxicity. Variables found to be significant on univariate analysis and were included in multivariable analysis. All *t*-tests were performed as two-tailed analyses, and a significance level of 0.05 was used for all statistical testing.

Results {#S0003}
=======

Population characteristics {#S20008}
--------------------------

The median age and initial PSA was 68 years (range: 45-87 years) and 6.1 ng/ml (range: 0.4-33.9 ng/ml), respectively. The median follow-up time for the study population was 8.8 years (range: 0.2-15.1 years) with a median number of 9 post PI PSA measurements (range: 0-41). The characteristics of the study population are as described in [Table 1](#T0001){ref-type="table"}, and dosimetric measurements and implant characteristics are described in [Table 2](#T0002){ref-type="table"}. Dosimetric parameters are compared between the WP, TZ, and PZ ([Table 3](#T0003){ref-type="table"}). As intended by peripheral loading of sources, the TZ received lower doses of radiation than the WP (*p* \< 0.0001), which in turn received lower doses than the PZ (*p* \< 0.0001).

###### 

Intra- and post-implantation variables

  Variable                          Median   Range
  --------------------------------- -------- -------------
  Number of sources                 104      56-221
  Activity (U)                      0.430    0.337-0.546
  Number of needles used            28       16-50
  Pre-PI prostate volume (cm^3^)    34.5     13.7-122.5
  Length (cm)                       4.5      2.6-7.0
  Width (cm)                        4.9      2.2-7.0
  Height (cm)                       3.1      2.0-6.4
  Post-PI prostate volume (cm^3^)   31.3     8.0-115.7

U -- air KERMA units, PI -- prostate implant

###### 

Zone-specific dosimetric parameters assessed on post-implant computed tomography

  Variable                   WP                   TZ                   PZ                   TZ vs. WP   PZ vs. WP   TZ vs. PZ
  -------------------------- -------------------- -------------------- -------------------- ----------- ----------- -----------
  D~90~ \[Gy (range)\]       141.2 (66.0-222.6)   134.5 (55.3-219.5)   156.1 (73.4-239.9)   \< 0.0001   \< 0.0001   \< 0.0001
  D~100~ \[Gy (range)\]      80.7 (32.1-155.2)    91.5 (34.5-184.6)    85.5 (37.7-155.0)    \< 0.0001   \< 0.0001   \< 0.0001
  Volume \[cm^3^ (range)\]   31.3 (8.0-115.7)     10.2 (1.5-41.8)      20.2 (5.9-75.8)      --          --          --
  V~100~ \[% (range)\]       88.8 (39.0-100.0)    84.2 (12.6-100.0)    93.3 (52.0-100.0)    \< 0.0001   \< 0.0001   \< 0.0001
  V~150~ \[% (range)\]       52.6 (9.7-93.3)      29.0 (1.9-94.2)      63.7 (11.9-94.4)     \< 0.0001   \< 0.0001   \< 0.0001
  V~200~ \[% (range)\]       23.6 (4.1-64.2)      9.0 (0.8-46.5)       31.0 (4.5-76.9)      \< 0.0001   \< 0.0001   \< 0.0001
  V~300~ \[% (range)\]       7.0 (2.0-23.9)       3.3 (0.0-13.5)       8.5 (1.8-32.0)       \< 0.0001   \< 0.0001   \< 0.0001
  V~400~ \[% (range)\]       3.8 (0.6-11.3)       2.0 (0.0-6.9)        4.5 (1.0-13.9)       \< 0.0001   \< 0.0001   \< 0.0001

Pairwise statistical testing was performed using two-tailed t-tests.

WP -- whole prostate, TZ -- transition zone, PZ -- peripheral zone, D~90~ -- minimum dose received by 90% of the anatomic volume, D~100~ -- minimum dose received by 100% of the anatomic volume, V~100~ -- volume of the anatomic volume receiving 100% of the prescribed dose, V~150~ -- volume of the anatomic volume receiving 150% of the prescribed dose, V~200~ -- volume of the anatomic volume receiving 200% of the prescribed dose, V~300~ -- volume of the anatomic volume receiving 300% of the prescribed dose, V~400~ -- volume of the anatomic volume receiving 400% of the prescribed dose

Biochemical failure {#S20009}
-------------------

The 5-year and 10-year rates for biochemical recurrence-free survival were 92.4% (95% CI: 89.6-95.3%) and 82.4% (95% CI: 77.2-87.7%) ([Fig. 2](#F0002){ref-type="fig"}). The 5-year and 10-year rates for distant metastasis-free survival were 97.8% (95% CI: 96.2-99.4%) and 92.4% (95% CI: 88.4-96.5%). The 5-year and 10-year rates for prostate cancer-specific mortality were 0.58% (95% CI: 0-1.37%) and 0.97% (95% CI: 0-2.08%).

![Kaplan-Meier curve depicting biochemical relapsefree survival. Only patients with three or more PSAs were included for this analysis. N indicates the number of patients at risk at each time point](JCB-7-24538-g002){#F0002}

On univariate Cox proportional hazards regression analysis, initial PSA, Gleason 7+ disease, duration of ADT, WP V~100~, TZ V~100~, TZ D~90~, PZ V~100~, length and width of the prostate, and PSA frequency were significant predictors for the presence/absence of biochemical failure ([Table 4](#T0004){ref-type="table"}). As PSA frequency is associated with biochemical failure, it was included in the multivariable analysis so that its effect can be adjusted for. On multivariable analysis of these variables, only initial PSA, Gleason 7+ disease, and PSA frequency remained significant ([Table 5](#T0005){ref-type="table"}).

###### 

Univariate analysis of clinical and dosimetric parameters as predictors for biochemical failure

  Variable                  Hazard ratio (95% CI)   *p*-value
  ------------------------- ----------------------- -----------
  Age                       0.988 (0.948-1.031)     0.5815
  Race (AA vs. non-AA)      1.560 (0.749-3.250)     0.2348
  T2bc vs. T1T2a            2.618 (0.633-10.870)    0.1838
  Initial PSA               1.106 (1.045-1.171)     0.0005
  Gleason score 7+          4.950 (2.740-9.009)     \< 0.0001
  Duration of ADT           1.129 (1.029-1.238)     0.0105
  WP V~100~ (%)             0.973 (0.949-0.998)     0.0321
  WP D~90~ (Gy)             0.989 (0.978-1.001)     0.0746
  TZ V~100~ (%)             0.985 (0.969-1.001)     0.0644
  TZ D~90~ (Gy)             0.989 (0.978-1.000)     0.0472
  PZ V~100~ (%)             0.966 (0.937-0.995)     0.0238
  PZ D~90~ (Gy)             0.993 (0.983-1.003)     0.1566
  Activity (U)              0.257 (0-1276)          0.7542
  Length (cm)               0.559 (0.356-0.878)     0.0117
  Width (cm)                0.485 (0.328-0.718)     0.0003
  Height (cm)               0.745 (0.429-1.291)     0.2938
  PSA frequency             13.766 (4.948-38.300)   \< 0.0001
  PSA frequency \*BF time   0.986 (0.966-1.006)     0.1696

AA -- African American, ADT -- androgen deprivation therapy, WP -- whole prostate, TZ -- transition zone, PZ -- peripheral zone, D~90~ -- minimum dose received by 90% of the anatomic volume, V~100~ -- volume of the anatomic volume receiving 100% of the prescribed dose, U -- air KERMA units, BF -- biochemical failure

###### 

Multivariable analysis of clinical and dosimetric parameters, which were significant on univariate analysis as predictors for biochemical failure

  Variable                  Hazard ratio (95% CI)   *p*-value
  ------------------------- ----------------------- -----------
  Initial PSA               1.123 (1.057-1.193)     0.0002
  Gleason score 7+          4.937 (2.507-9.721)     \< 0.0001
  Duration of ADT           0.884 (0.774-1.010)     0.0696
  WP V~100~ (%)             1.050 (0.910-1.210)     0.5045
  TZ D~90~ (Gy)             0.989 (0.963-1.017)     0.4357
  PZ V~100~ (%)             0.936 (0.835-1.049)     0.2560
  Length (cm)               0.760 (0.447-1.290)     0.3084
  Width (cm)                0.662 (0.401-1.090)     0.1052
  PSA frequency             17.838 (5.730-55.526)   \< 0.0001
  PSA frequency \*BF time   0.983 (0.962-1.004)     0.1113

ADT -- androgen deprivation therapy, WP -- whole prostate, TZ -- transition zone, PZ -- peripheral zone, D~90~ -- minimum dose received by 90% of the anatomic volume, V~100~ -- volume of the anatomic volume receiving 100% of the prescribed dose

Toxicity {#S20010}
--------

Thirty-six patients (8.7%) developed late grade 3 or higher GU toxicity, whereas 7 patients (1.7%) developed late grade 3 or higher GI toxicity ([Table 6](#T0006){ref-type="table"}). The 5-year and 10-year rates of grade 3 or higher GU toxicity was 6.1% (95% CI: 3.7-8.6%) and 10.9% (95% CI: 7.0-14.7%). The 5-year and 10-year rates of grade 3 or higher GI toxicity was 1.8% (0.5-3.2%) and 1.8% (0.5-3.2%). Genitourinary toxicity was classified as obstructive or irritative, and the grade 3 or greater GU toxicity was predominately because of the need to relieve urinary obstruction (94.4%). On univariate Cox proportional hazards regression, only V~200~ and V~300~ in the TZ was significantly associated with grade 3 or higher late GU toxicity ([Table 7](#T0007){ref-type="table"}). Age, race, duration of ADT, activity, prostate volume, length, width, height, TZ D~90~, TZ V~100~, TZ V~150~, TZ V~400~, TZ~Volume~, BMI, and history of diabetes were not. Due to the low event rate, Cox proportional hazards regression to identify factors predictive of late grade 3 or higher GI toxicity was not performed.

###### 

Late genitourinary and gastrointestinal toxicity stratified by toxicity grade

  Toxicity grade   Irritative genitourinary *n* (%)   Obstructive genitourinary *n* (%)   Total genitourinary *n* (%)   Total gastrointestinal *n* (%)
  ---------------- ---------------------------------- ----------------------------------- ----------------------------- --------------------------------
  None             376 (90.4%)                        375 (90.1%)                         335 (80.5%)                   398 (95.7%)
  Grade 1          5 (1.2%)                           0 (0%)                              5 (1.2%)                      3 (0.7%)
  Grade 2          33 (7.9%)                          7 (1.7%)                            40 (9.6%)                     8 (1.9%)
  Grade 3          2 (0.5%)                           33 (7.9%)                           35 (8.4%)                     7 (1.7%)
  Grade 4          0 (0%)                             1 (0.2%)                            1 (0.2%)                      0 (0%)
  Grade 5          0 (0%)                             0 (0%)                              0 (0%)                        0 (0%)

###### 

Univariate analysis of clinical and dosimetric parameters as predictors for late grade 3 or higher genitourinary toxicity

  Variable               Hazard ratio (95% CI)       *p-value*
  ---------------------- --------------------------- -----------
  Age                    1.048 (0.997-1.101)         0.0635
  Race (AA vs. non-AA)   0.981 (0.381-2.527)         0.9684
  Duration of ADT        0.990 (0.870-1.125)         0.8735
  Activity (U)           672.220 (0.048-9.361E+06)   0.1811
  Prostate volume        0.991 (0.969-1.015)         0.4702
  Length (cm)            0.973 (0.615-1.539)         0.9062
  Width (cm)             0.937 (0.600-1.461)         0.7727
  Height (cm)            0.599 (0.315-1.140)         0.1182
  TZ D90 (Gy)            0.999 (0.988-1.011)         0.9131
  TZ V100 (%)            1.001 (0.981-1.021)         0.9286
  TZ V150 (%)            1.008 (0.992-1.025)         0.3260
  TZ V200 (%)            1.043 (1.004-1.082)         0.0296\*
  TZ V300 (%)            1.163 (1.006-1.344)         0.0408\*
  TZ V400 (%)            1.232 (0.952-1.595)         0.1132
  TZ Volume (cm^3^)      1.001 (0.946-1.059)         0.9762
  BMI (kg/m^2^)          0.931 (0.858-1.012)         0.0920
  Diabetes (N vs. Y)     1.406 (0.547-3.623)         0.4786

AA -- African American, TZ -- transition zone, BMI -- body mass index, D~90~ -- minimum dose received by 90% of the anatomic volume, V~100~ -- volume of the anatomic volume receiving 100% of the prescribed dose, V~150~ -- volume of the anatomic volume receiving 150% of the prescribed dose, V~200~ -- volume of the anatomic volume receiving 200% of the prescribed dose, V~300~ -- volume of the anatomic volume receiving 300% of the prescribed dose, V~400~ -- volume of the anatomic volume receiving 400% of the prescribed dose

Discussion {#S0004}
==========

Although there are established guidelines for PI target dosage, this study demonstrates that radiation dose delivered to the prostate is not uniform. At our institution, the peripheral distribution of sources is intended to reduce radiation dose delivered to the urethra within the constraints of whole prostate dosimetry guidelines.

Based on target dosimetric parameters for the whole prostate, the TZ appears to be underdosed. Yet, on multivariable analysis, neither WP nor zone-specific dosimetry was significantly associated with biochemical failure, suggesting that overall, lower TZ dose is not necessarily associated with worse outcomes. In the absence of significant benign prostate hypertrophy, the PZ constitutes the majority of prostate \[[@CIT0014]\]. The majority of prostate cancers arise from the PZ, which tends to receive a higher treatment dose, using the technique described here, than WP dosimetry would suggest. In this analysis, the 10-year rates of late grade 3 or higher GU and GI toxicity was 10.9% and 1.8%. In addition, the TZ volume, which receives particularly high doses, as characterized by V~200~ and V~300~, may be associated with increased late GU toxicity, a finding which has been consistently observed in HDR brachytherapy studies having less follow-up than this series \[[@CIT0015]--[@CIT0017]\]. This is likely due to islands of high dose that are in close proximity to the urethra. High-dose-rate brachytherapy has the technical advantage of control over post-implant dosimetry, although it is much more invasive than LDR brachytherapy \[[@CIT0018]\]. While there is some evidence to suggest that prostate length is associated with late GU toxicity likely due to greater medial lobe size and correspondingly higher doses to the bladder neck, presumably due to backscatter from the medial lobe to the bladder neck, our data did not demonstrate such a relationship \[[@CIT0019]--[@CIT0021]\].

The rates of long-term biochemical failure and late toxicities following the use of brachytherapy for prostate cancer with or without EBRT have been investigated in RTOG 00-19 and RTOG 98-05 \[[@CIT0022], [@CIT0023]\]. In RTOG 00-19, which combined brachytherapy with EBRT, there was a 15% rate of grade 3 or higher GU/GI toxicities after four years, even though the target dose of PI was lowered to 108 Gy to account for the addition of EBRT \[[@CIT0022]\]. In contrast, the rate of late (beyond 9 months) grade 3 toxicities was 3.2% in RTOG 98-05 using the same protocol management as RTOG 00-19 \[[@CIT0023]\]. The high degree of variation in toxicity may be due to the oversimplification of treating the whole prostate as a single homogenous organ. It is also possible that the grading of toxicity can be highly subjective and that patient selection may play a role. In our series, a simple urethral dilation was graded as a grade 3 GU toxicity as was a TURP or similar procedure, in which prostate tissue was removed to relieve obstruction. We also had no pre-treatment selection bias relative to urinary function while RTOG 98-05 required all patients to have an AUA voiding score of \< 18. Even if V~100~ and D~90~ are similar for two patients, there can be substantial differences in dose distributions, suggesting that standard dosimetric parameters may not be fully representative of the implant quality and dose distribution \[[@CIT0024]\]. It is interesting to note that shorter width and length were significant predictors of biochemical failure on univariate analysis, as the TZ is closer to the PZ, and these glands would be more difficult to implant.

Given the learning curve of prostate brachytherapy, in RTOG 00-19 it would not be unusual that centers with less accrual would deliver higher treatment doses based on dosimetric quantifiers than centers with more experience, as a higher treatment dose is not necessarily a superior treatment \[[@CIT0025], [@CIT0026]\]. An even distribution of seeds results in uneven dose distributions, with the central region receiving a higher dose, and an overtreatment of the urethra, as well as surrounding organs may also contribute to higher than expected genitourinary toxicity \[[@CIT0027]\]. In contrast to EBRT, which delivers a relatively homogenous treatment dose to the tissues within the beam, the advantage of brachytherapy is the ability to deliver a higher dose to the prostate as a whole, while being able to manipulate the dose distribution within the prostate to account for zonal anatomy by judicious placement of sources. As such, attention to dose painting is critical for tumor control and limiting toxicities. This is especially important for patients at higher risk of significant toxicity, such as those with a history of TURP \[[@CIT0028]\].

Limitations of this study include its retrospective nature, as well as the reflection of outcomes at a single tertiary-care referral center. As prostate zonal anatomy is not clearly visualized on CT, there may be significant variability in contouring, although a standardized method was used in order to minimize this effect \[[@CIT0029]\].

Conclusions {#S0005}
===========

In conclusion, dose distribution within the prostate can be heterogeneous and standard whole prostate dosimetric parameters based on a prescription dose may not be fully representative of implant quality \[[@CIT0030]\]. Acceptable clinical outcomes can be obtained even when the TZ systematically receives a lower radiation dose than the rest of the prostate to spare the urethra. Increased awareness of zonal anatomy of the prostate during treatment planning may reduce late toxicities without sacrificing efficacy.

The work has been presented as a poster at the 56^th^ ASTRO 2014 Annual Meeting.
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